• The number of participating sites and countries were updated. • A footnote was added to the primary hypothesis for the purpose of clarification and alignment with the timeframe for analysis. • The wording of secondary endpoints 1(a) and 1(b) were modified to more accurately state that all AEs, not just SAEs were to be reported through the entire duration that a subject was in the clinical trial. • Exploratory objective 2 and associated endpoints were removed. • The wording of secondary objective 8 was revised to reflect more clearly that immunology results were to be assessed relative to baseline levels. • For exploratory objective 3, DNA methylation was added to investigate as an additional potential biomarker. • Exploratory endpoint 4 was added to describe the association of the baseline tissue-based score derived using immunologic markers (immunoscore) to the Week 36 efficacy endpoint. • Text was clarified in the immunogenicity assessment, safety assessment, and trial population sections of the synopsis. • Human leukocyte antigen (HLA) testing was removed. • Revisions to the inclusion and exclusion criteria (synopsis, Sections 4.1, and 4.2) • Updates to the Schedule of Events table • General updates and clarifications Additional minor grammatical and administrative changes were made throughout the document for improvement of general readability.

• The EudraCT number was added to the protocol. • The number of participating countries was changed from 15 to 20. This change was made to the protocol synopsis. • The protocol was updated throughout to remove the digital photography procedure. • In Section 5.10.2 CELLECTRA™ 5PSP Device, wording was added to allow sites either to ship unused CELLECTRA™ 5PSP arrays back to Inovio or to destroy them on-site. • In Section 5.10.2 CELLECTRA™ 5PSP Device, text was updated as follows: upon completion or termination of ‘the study’ was replaced by ‘Inovio’s studies’, to indicate that the Base Station and Handset must be returned to Inovio Pharmaceuticals, Inc after completion of Inovio’s studies utilizing the CELLECTRA™ 5PSP device. • In Section 8.5.2.2 Immunogenicity, the Week 8 immunogenicity evaluation was removed from the text.

• The primary population to which the primary objective was applied was changed from “all subjects” to “subjects defined as biomarker-positive at baseline,” as identified by microRNA (miRNA) profiling performed from peripheral blood prior to dosing with VGX-3100 (Section 6.10). This change was made in order to define a population of patients in whom VGX-3100 is more likely to be efficacious as defined by the primary endpoint of regression of cervical HSIL and clearance of HPV-16/18. • The protocol was revised to remove 4-quadrant biopsy as a potential procedure at Week 36 throughout the protocol. • Stopping Rules (Criteria for Pausing of Study) added to Data Safety Monitoring Board Charter version 3.0. • Updated acceptable contraception methods in Protocol Synopsis, Inclusion Criteria and Section 4.1, Inclusion Criteria. A footnote was added to clarify that use of condoms or condoms and spermicide are not acceptable forms of contraception. • Updated Table 1: Schedule of Events and Sections 6.1.1, 6.1.2, and 6.4.12, method of collection for cervical digene™ samples. Text was changed and updated the method of collection of cervical digene™ samples from swabs to brushes at screening, Day 0, Weeks 15, 28, and 36. • Clarifications on different sections added. • Administrative Changes.